Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 15/20 | 0.39 |
| ▸ | CHRNA4 | P43681 | 15/20 | 0.39 |
| ▸ | CHRNB4 | P30926 | 12/20 | 0.39 |
| ▸ | CHRNA3 | P32297 | 12/20 | 0.39 |
| ▸ | CHRNA7 | P36544 | 9/20 | 0.37 |
| ▸ | SOST | Q9BQB4 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3232278 | 0.85 | CHRNB2 (0.42) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL17035440 | 0.82 | SOST (0.36) | CHRNB2CHRNA4CHRNB4CHRNA3SOST | |
| SCHEMBL3233238 | 0.81 | CHRNB2 (0.44) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL3231522 | 0.81 | CHRNB2 (0.47) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL3237302 | 0.80 | CHRNB2 (0.51) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL3233399 | 0.80 | KDM4E (0.43) | POLB | |
| SCHEMBL3241059 | 0.79 | L3MBTL1 (0.39) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL25355436 | 0.79 | CHRNB2 (0.38) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL29850875 | 0.79 | CHRNB2 (0.38) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL3235805 | 0.77 | CHRNB2 (0.56) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010028011-A1 | AMIDES OF DIAZABICYCLONONANES AND USES THEREOF | TARGACEPT, INC. (US) | 2010-03-11 | — | — | WO | disclosed |